Product Name :
Fexofenadine HCl
Description:
Fexofenadine inhibits histamine H1 receptor with IC50 of 246 nM.
CAS:
153439-40-8
Molecular Weight:
538.12
Formula:
C32H40ClNO4
Chemical Name:
2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid hydrochloride
Smiles :
Cl.CC(C)(C1C=CC(=CC=1)C(O)CCCN1CCC(CC1)C(O)(C1C=CC=CC=1)C1C=CC=CC=1)C(O)=O
InChiKey:
RRJFVPUCXDGFJB-UHFFFAOYSA-N
InChi :
InChI=1S/C32H39NO4.ClH/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Fexofenadine inhibits histamine H1 receptor with IC50 of 246 nM.|Product information|CAS Number: 153439-40-8|Molecular Weight: 538.12|Formula: C32H40ClNO4|Chemical Name: 2-(4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid hydrochloride|Smiles: Cl.CC(C)(C1C=CC(=CC=1)C(O)CCCN1CCC(CC1)C(O)(C1C=CC=CC=1)C1C=CC=CC=1)C(O)=O|InChiKey: RRJFVPUCXDGFJB-UHFFFAOYSA-N|InChi: InChI=1S/C32H39NO4.ClH/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 107 mg/mL(198.84 mM). Water: 2 mg/mL(3.71 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Fexofenadine exhibits a potent and concentration-dependent anti-anaphylactic activity with an IC50 value of 95.5nM. Fexofenadine shows only a weak competitive antagonist behaviour for the 5-HT2A receptorsfrom rat caudal artery with pA2 of 5.2. All four P-gp inhibitors has a strong, concentration-dependent effect on the Papp of fexofenadine in both directions in the Caco-2 cell model. The IC50 of verapamil is 8.44 mM on the P-gp-mediated secretion of Fexofenadine. Fexofenadine causes a significant increase in the QT and Tp-e intervals and receives a significant TdP score at doses greater than 100 fold its free TPC in the rabbit left ventricular wedge preparation.{{IL-10 Protein, Mouse} MedChemExpress|{IL-10 Protein, Mouse} Technical Information|{IL-10 Protein, Mouse} In Vivo|{IL-10 Protein, Mouse} custom synthesis|{IL-10 Protein, Mouse} Autophagy} |In Vivo:|Fexofenadine is excreted unchanged in the urine, bile, and gastrointestinal tract, indicating minimal metabolism in rats, making it an ideal probe to study transport processes.{{Puromycin} web|{Puromycin} Immunology/Inflammation|{Puromycin} Purity & Documentation|{Puromycin} Formula|{Puromycin} custom synthesis} Coadministration of Fexofenadine with Ketoconazole increases the oral exposure of Fexofenadine by 187% in rats.PMID:23833812 In contrast, coadministration of Fexofenadine with orange juice or apple juice to rats decreases the oral exposure of Fexofenadine by 31% and 22%, respectively. Increasing the quantity of orange or apple juice administered further decreases the oral exposure of Fexofenadine, by 40% and 28%, respectively. Biliary excretion clearance of Fexofenadine (17 ml/min/kg) accounts for almost 60% of the total body clearance (30 ml/min/kg) in mice. Knockout mice of Mdr1a/1b P-gp does not affect the biliary excretion clearance with regard to both plasma and liver concentrations, whereas the absence of P-gp causes a 6-fold increase in the plasma concentration and 3-fold higher brain-to-plasma concentration ratio after oral administration.|References:|Liu T, et al. Heart Rhythm, 2006, 3(8), 948-956.Petri N, et al. Pharm Res, 2004, 21(8), 1398-1404.Corcóstegui R, et al. Drugs R D, 2005, 6(6), 371-38Products are for research use only. Not for human use.|
